Testing a new drug for liver scarring from MASH
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug called pegozafermin to see if it can help people with cirrhosis (scarring) of the liver caused by MASH (a fatty liver disease). If you have cirrhosis and either diabetes or multiple risk factors, this study might be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have type 2 diabetes or at least two metabolic risk factors (like high blood pressure or high cholesterol).
- You have cirrhosis (scarring) of the liver caused by MASH (a type of fatty liver disease), confirmed by a liver biopsy.
- Your body mass index (BMI) is at least 25 (or 23 if you are Asian) and less than 50.
- You do not have another liver disease, liver cancer, or a history of liver failure (like fluid in the belly or yellowing of the skin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how your body processes a new medication called miricorilant, designed to help people with fatty liver disease (MASH). You'll have liver scans or recent biopsy results and metabolic conditions like diabetes or high blood pressure.
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
This trial tests whether efimosfermin, an experimental drug, can safely help people with MASH (a fatty liver disease) that has led to cirrhosis (liver scarring) but the liver is still working well (compensated). Participants will be randomly assigned to receive the drug or a placebo.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
Hear when a new Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.